60
Antipsychotic medicines are a key part of the pharmacological treatment of schizophrenia. Although they provide therapeutic benefits, they are constrained by well-recognised limitations in terms of efficacy and tolerability.1 Over the last few decades, hundreds of randomised controlled trials (RCTs) have investigated the benefits and harms of these medicines in different populations with schizophrenia and related psychotic disorders. These studies have been summarised in systematic reviews, which have informed clinical guidelines and provided useful insights for everyday clinical practice.
